Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11489261rdf:typepubmed:Citationlld:pubmed
pubmed-article:11489261lifeskim:mentionsumls-concept:C0242643lld:lifeskim
pubmed-article:11489261lifeskim:mentionsumls-concept:C0000097lld:lifeskim
pubmed-article:11489261lifeskim:mentionsumls-concept:C0000098lld:lifeskim
pubmed-article:11489261lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:11489261lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:11489261lifeskim:mentionsumls-concept:C2347946lld:lifeskim
pubmed-article:11489261lifeskim:mentionsumls-concept:C0205198lld:lifeskim
pubmed-article:11489261pubmed:issue1-2lld:pubmed
pubmed-article:11489261pubmed:dateCreated2001-8-7lld:pubmed
pubmed-article:11489261pubmed:abstractTextThe vesicular monoamine transporter 2 (VMAT2) has sequence homology with bacterial multidrug transporters which in turn share homology with mammalian P-glycoprotein (P-GP). Both VMAT2 and P-GP can detoxify cells. 1-Methyl-4-phenylpyridinium (MPP(+)), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), is a substrate for VMAT2 that has several structural features in common with P-GP substrates and inhibitors. The present studies investigated whether P-GP is responsible for the elimination of MPP(+) from the brain. Additionally, VMAT2 and P-GP are inhibited by many of the same compounds. Thus we also investigated whether VMAT2 inhibitors could block P-GP in vitro and vice versa whether P-GP inhibitors could block VMAT2 mediated transport of [3H]-DA into synaptic vesicles. In mice treated with MPTP and a P-GP inhibitor (quinidine, trans-flupentixol or cyclosporine A), the elimination of MPP(+) from the striatum was significantly delayed. However, in experiments using various cell lines expressing either mouse or human P-GP, MPP(+) did not reverse the P-GP mediated resistance to vincristine, suggesting that MPP(+) is a poor substrate for P-GP. Additional experiments were performed using mdr1a/b double knockout mice which lack functional P-GP encoded by these two genes. Data from mdr1a/b knockout mice treated with MPTP also suggest that MPP(+) is not extruded from the brain by P-GP. In other studies, we demonstrated that the VMAT2 inhibitors tetrabenazine and Ro 4-1284 inhibit P-GP and that the P-GP inhibitors trans-flupentixol and quinidine inhibit VMAT2. Thus, several new drugs can be added to the list of compounds that are able to inhibit both VMAT2 and P-GP, providing further evidence of the similarity between these two transporters.lld:pubmed
pubmed-article:11489261pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:languageenglld:pubmed
pubmed-article:11489261pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:citationSubsetIMlld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11489261pubmed:statusMEDLINElld:pubmed
pubmed-article:11489261pubmed:monthAuglld:pubmed
pubmed-article:11489261pubmed:issn0006-8993lld:pubmed
pubmed-article:11489261pubmed:authorpubmed-author:HaitW NWNlld:pubmed
pubmed-article:11489261pubmed:authorpubmed-author:YangJ MJMlld:pubmed
pubmed-article:11489261pubmed:authorpubmed-author:SonsallaP KPKlld:pubmed
pubmed-article:11489261pubmed:authorpubmed-author:StaalR GRGlld:pubmed
pubmed-article:11489261pubmed:issnTypePrintlld:pubmed
pubmed-article:11489261pubmed:day10lld:pubmed
pubmed-article:11489261pubmed:volume910lld:pubmed
pubmed-article:11489261pubmed:ownerNLMlld:pubmed
pubmed-article:11489261pubmed:authorsCompleteYlld:pubmed
pubmed-article:11489261pubmed:pagination116-25lld:pubmed
pubmed-article:11489261pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:meshHeadingpubmed-meshheading:11489261...lld:pubmed
pubmed-article:11489261pubmed:year2001lld:pubmed
pubmed-article:11489261pubmed:articleTitleInteractions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.lld:pubmed
pubmed-article:11489261pubmed:affiliationDepartment of Neurology, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854-4535, USA.lld:pubmed
pubmed-article:11489261pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11489261pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed